Triethylene Thiophosphoramide for Breast Cancer Treatment
Author Information
Author(s): K. J. Gurling
Primary Institution: Royal Free Hospital and School of Medicine, London
Hypothesis
Can triethylene thiophosphoramide improve outcomes in patients with breast cancer who have undergone hypophysectomy?
Conclusion
Triethylene thiophosphoramide led to objective improvement in 56% of patients with advanced breast cancer who had previously undergone hypophysectomy.
Supporting Evidence
- 56% of patients showed objective improvement after treatment with thiotepa.
- Seven patients maintained improvement for eight weeks or more.
- Four patients experienced significant relief from bone pain due to metastases.
Takeaway
This study tested a drug called thiotepa on women with breast cancer who had surgery that usually doesn't help them anymore, and it worked for some of them.
Methodology
Patients received intramuscular injections of thiotepa, starting with 5 mg daily for five days, with adjustments based on blood cell counts.
Limitations
The study had a small sample size and the improvements were often temporary.
Participant Demographics
Eighteen women who had previously undergone surgical hypophysectomy.
Want to read the original?
Access the complete publication on the publisher's website